ArticleThe Lancet regional health. Western Pacific2026
Clinical characteristics, treatment patterns, and costs among hospitalised patients with cardiomyopathy: a multicentre retrospective tertiary-hospital study across China.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Characterising treatment patterns and costs is essential for understanding healthcare utilisation and informing cost management. We aimed to assess these aspects among hospitalised patients with cardiomyopathy. Methods: We conducted a multicentre study at 11 tertiary hospitals across China, systematically extracting electronic medical records from 2017 to 2022. Factors associated with medical costs were analysed using generalised linear regression with cluster-robust standard errors. Findings: Among 15,764 medical records of adult inpatients with cardiomyopathy, medical therapy alone (81.5%; 12,853/15,764) was the most common treatment pattern. The mean direct medical cost per hospitalisation for all admissions was $6294 ($11,564) and the median cost was $2152 (IQR $1248, $4931), with variation across cardiomyopathy subtypes. Admissions to the national centre (Exp(β) 1.529 [95% confidence interval 1.242-1.882]), New York Heart Association functional class III/IV (Exp(β) 1.371 [1.169-1.608]), and combination therapies (vs. medical therapy alone: medical and interventional Exp(β) 6.685 [5.098-8.766]; medical and surgical 7.537 [6.213-9.143]; all three 10.718 [7.579-15.157]) were associated with higher costs, whereas insurance coverage (Exp(β) 0.773 [0.642-0.932]) was associated with lower costs. Interpretation: This study provides evidence on inpatient medical costs and their associated factors, serving as a reference for understanding the real-world cost profile and informing cost management of cardiomyopathy in tertiary healthcare settings. Funding: The Noncommunicable Chronic Diseases-National Science and Technology Major Project, the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences, the National High Level Hospital Clinical Research Funding, and the Science and Technology Department of Heilongjiang Province.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.